Skye Bioscience (SKYE) Tax Provisions (2013 - 2025)
Skye Bioscience (SKYE) posted quarterly Tax Provisions of $3400.0 for Q2 2025, down 57.87% year-over-year from $8071.0 in Q2 2024, and up 70.0% quarter-over-quarter from $2000.0 in Q1 2025.
Skye Bioscience (SKYE) Tax Provisions (2013 - 2025) Analysis & Trends
Skye Bioscience (SKYE) has reported Tax Provisions for 13 consecutive years, with $3400.0 the latest figure, recorded in Q2 2025.
- In Q2 2025, Tax Provisions fell 57.87% year-over-year to $3400.0; the TTM figure through Mar 2026 stood at $3400.0 (down 66.24% YoY), while the FY2025 annual figure was $5400.0, down 46.38% from the prior year.
- Tax Provisions climbed to $3400.0 in Q2 2025 per SKYE's latest filing, from $2000.0 in the prior quarter.
- Across five years, Tax Provisions topped out at $8071.0 in Q2 2024 and bottomed at $500.0 in Q4 2021.
- Historically, Tax Provisions has averaged $3101.3 across 5 years, with a median of $2000.0 in 2024.
- Annual changes were most pronounced in 2022 — Tax Provisions surged 221.31% — and 2025, when it sank 57.87%.
- Skye Bioscience's Tax Provisions stood at $500.0 in 2021, then jumped by 220.0% to $1600.0 in 2022, then soared by 125.0% to $3600.0 in 2023, then soared by 124.19% to $8071.0 in 2024, then tumbled by 57.87% to $3400.0 in 2025.
- Business Quant data shows SKYE's Tax Provisions at $3400.0 in Q2 2025, $2000.0 in Q1 2025, and $8071.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 59.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 15.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 75.45 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 13.31 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.90 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -90.33 Mn |
| 10 | Skye Bioscience | 11.17 Mn | 11.17 Mn | - | 3,400.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 3,400.00 |
| Mar 31, 2025 | 2,000.00 |
| Jun 30, 2024 | 8,071.00 |
| Mar 31, 2024 | 2,000.00 |
| Jun 30, 2023 | 3,600.00 |
| Dec 31, 2022 | 1,600.00 |
| Jun 30, 2022 | 5,141.00 |
| Dec 31, 2021 | 500.00 |
| Jun 30, 2021 | 1,600.00 |
| Jun 30, 2020 | 1,600.00 |
| Jun 30, 2019 | 1,600.00 |
| Jun 30, 2018 | 1,642.00 |
| Dec 31, 2017 | -831.00 |
| Jun 30, 2017 | 1,600.00 |
| Mar 31, 2017 | 831.00 |
| Dec 31, 2016 | 400.00 |
| Sep 30, 2016 | 400.00 |
| Jun 30, 2016 | 400.00 |
| Mar 31, 2016 | 400.00 |
| Dec 31, 2015 | 400.00 |